Literature DB >> 19492347

Prostate cancer segregation analyses using 4390 families from UK and Australian population-based studies.

Robert J MacInnis1, Antonis C Antoniou, Rosalind A Eeles, Gianluca Severi, Michelle Guy, Lesley McGuffog, Amanda L Hall, Lynne T O'Brien, Rosemary A Wilkinson, David P Dearnaley, Audrey T Ardern-Jones, Alan Horwich, Vincent S Khoo, Christopher C Parker, Robert A Huddart, Margaret R McCredie, Charmaine Smith, Melissa C Southey, Margaret P Staples, Dallas R English, John L Hopper, Graham G Giles, Douglas F Easton.   

Abstract

Familial aggregation of prostate cancer is likely to be due to multiple susceptibility loci, perhaps acting in conjunction with shared lifestyle risk factors. Models that assume a single mode of inheritance may be unrealistic. We analyzed genetic models of susceptibility to prostate cancer using segregation analysis of occurrence in families ascertained through population-based series totaling 4390 incident cases. We investigated major gene models (dominant, recessive, general, X-linked), polygenic models, and mixed models of susceptibility using the pedigree analysis software MENDEL. The hypergeometric model was used to approximate polygenic inheritance. The best-fitting model for the familial aggregation of prostate cancer was the mixed recessive model. The frequency of the susceptibility allele in the population was estimated to be 0.15 (95% confidence interval (CI) 0.11-0.20), with a relative risk for homozygote carriers of 94 (95% CI 46-192), and a polygenic standard deviation of 2.01 (95% CI 1.72-2.34). These analyses suggest that one or more genes having a strong recessively inherited effect on risk, as well as a number of genes with variants having small multiplicative effects on risk, may account for the genetic susceptibility to prostate cancer. The recessive component would predict the observed higher familial risk for siblings of cases than for fathers, but this could also be due to other factors such as shared lifestyle by siblings, targeted screening effects, and/or non-additive effects of one or more genes.

Entities:  

Mesh:

Year:  2010        PMID: 19492347     DOI: 10.1002/gepi.20433

Source DB:  PubMed          Journal:  Genet Epidemiol        ISSN: 0741-0395            Impact factor:   2.135


  15 in total

1.  A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact.

Authors:  Robert J Macinnis; Antonis C Antoniou; Rosalind A Eeles; Gianluca Severi; Ali Amin Al Olama; Lesley McGuffog; Zsofia Kote-Jarai; Michelle Guy; Lynne T O'Brien; Amanda L Hall; Rosemary A Wilkinson; Emma Sawyer; Audrey T Ardern-Jones; David P Dearnaley; Alan Horwich; Vincent S Khoo; Christopher C Parker; Robert A Huddart; Nicholas Van As; Margaret R McCredie; Dallas R English; Graham G Giles; John L Hopper; Douglas F Easton
Journal:  Genet Epidemiol       Date:  2011-07-18       Impact factor: 2.135

2.  [Ten years national research project "familial prostate cancer": problems in identifying risk families].

Authors:  K Herkommer; C Schmidt; J E Gschwend
Journal:  Urologe A       Date:  2011-07       Impact factor: 0.639

3.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

4.  Prostate cancer risk-associated genetic markers and their potential clinical utility.

Authors:  Jianfeng Xu; Jielin Sun; S Lilly Zheng
Journal:  Asian J Androl       Date:  2013-04-08       Impact factor: 3.285

5.  Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci.

Authors:  Ali Amin Al Olama; Sara Benlloch; Antonis C Antoniou; Graham G Giles; Gianluca Severi; David E Neal; Freddie C Hamdy; Jenny L Donovan; Kenneth Muir; Johanna Schleutker; Brian E Henderson; Christopher A Haiman; Fredrick R Schumacher; Nora Pashayan; Paul D P Pharoah; Elaine A Ostrander; Janet L Stanford; Jyotsna Batra; Judith A Clements; Suzanne K Chambers; Maren Weischer; Børge G Nordestgaard; Sue A Ingles; Karina D Sorensen; Torben F Orntoft; Jong Y Park; Cezary Cybulski; Christiane Maier; Thilo Doerk; Joanne L Dickinson; Lisa Cannon-Albright; Hermann Brenner; Timothy R Rebbeck; Charnita Zeigler-Johnson; Tomonori Habuchi; Stephen N Thibodeau; Kathleen A Cooney; Pierre O Chappuis; Pierre Hutter; Radka P Kaneva; William D Foulkes; Maurice P Zeegers; Yong-Jie Lu; Hong-Wei Zhang; Robert Stephenson; Angela Cox; Melissa C Southey; Amanda B Spurdle; Liesel FitzGerald; Daniel Leongamornlert; Edward Saunders; Malgorzata Tymrakiewicz; Michelle Guy; Tokhir Dadaev; Sarah J Little; Koveela Govindasami; Emma Sawyer; Rosemary Wilkinson; Kathleen Herkommer; John L Hopper; Aritaya Lophatonanon; Antje E Rinckleb; Zsofia Kote-Jarai; Rosalind A Eeles; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-04-02       Impact factor: 4.254

Review 6.  The genetic epidemiology of prostate cancer and its clinical implications.

Authors:  Rosalind Eeles; Chee Goh; Elena Castro; Elizabeth Bancroft; Michelle Guy; Ali Amin Al Olama; Douglas Easton; Zsofia Kote-Jarai
Journal:  Nat Rev Urol       Date:  2013-12-03       Impact factor: 14.432

7.  Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.

Authors:  Ali Amin Al Olama; Tokhir Dadaev; Dennis J Hazelett; Qiuyan Li; Daniel Leongamornlert; Edward J Saunders; Sarah Stephens; Clara Cieza-Borrella; Ian Whitmore; Sara Benlloch Garcia; Graham G Giles; Melissa C Southey; Liesel Fitzgerald; Henrik Gronberg; Fredrik Wiklund; Markus Aly; Brian E Henderson; Fredrick Schumacher; Christopher A Haiman; Johanna Schleutker; Tiina Wahlfors; Teuvo L Tammela; Børge G Nordestgaard; Tim J Key; Ruth C Travis; David E Neal; Jenny L Donovan; Freddie C Hamdy; Paul Pharoah; Nora Pashayan; Kay-Tee Khaw; Janet L Stanford; Stephen N Thibodeau; Shannon K Mcdonnell; Daniel J Schaid; Christiane Maier; Walther Vogel; Manuel Luedeke; Kathleen Herkommer; Adam S Kibel; Cezary Cybulski; Dominika Wokołorczyk; Wojciech Kluzniak; Lisa Cannon-Albright; Hermann Brenner; Katja Butterbach; Volker Arndt; Jong Y Park; Thomas Sellers; Hui-Yi Lin; Chavdar Slavov; Radka Kaneva; Vanio Mitev; Jyotsna Batra; Judith A Clements; Amanda Spurdle; Manuel R Teixeira; Paula Paulo; Sofia Maia; Hardev Pandha; Agnieszka Michael; Andrzej Kierzek; Koveela Govindasami; Michelle Guy; Artitaya Lophatonanon; Kenneth Muir; Ana Viñuela; Andrew A Brown; Mathew Freedman; David V Conti; Douglas Easton; Gerhard A Coetzee; Rosalind A Eeles; Zsofia Kote-Jarai
Journal:  Hum Mol Genet       Date:  2015-05-29       Impact factor: 6.150

8.  Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis.

Authors:  Nora Pashayan; Stephen W Duffy; David E Neal; Freddie C Hamdy; Jenny L Donovan; Richard M Martin; Patricia Harrington; Sara Benlloch; Ali Amin Al Olama; Mitul Shah; Zsofia Kote-Jarai; Douglas F Easton; Rosalind Eeles; Paul D Pharoah
Journal:  Genet Med       Date:  2015-01-08       Impact factor: 8.822

9.  Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E.

Authors:  Robert J MacInnis; Gianluca Severi; Laura Baglietto; James G Dowty; Mark A Jenkins; Melissa C Southey; John L Hopper; Graham G Giles
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

Review 10.  The genomic landscape of prostate cancer.

Authors:  Lien Spans; Liesbeth Clinckemalie; Christine Helsen; Dirk Vanderschueren; Steven Boonen; Evelyne Lerut; Steven Joniau; Frank Claessens
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.